Company Description
Alcon sees all, and hopes you can too. Through its Alcon Laboratories subsidiary, Alcon sells ophthalmic surgical and pharmaceutical products and...
Key Alcon Financials
| Company Type | Public - NYSE: ACL Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $5,599.6 |
| 2006 Employees | 13,500 |
More Alcon Financials (11 pages)
Latest Alcon Jobs jobs by Indeed
Rankings
- #209 in FT Global 500
Competition
Competitive Landscape for Medical Supplies and Devices
Demand is driven by population demographics and advances in medical knowledge and technology. The profitability of individual companies depends on the ability to develop superior...
Read more about Alcon's competition across multiple industries
Top Alcon Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Alcon Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman, President, and CEO; President and CEO, Alcon Laboratories | Cary R. Rayment | Network | E-mail |
| SVP Global Markets and Chief Marketing Officer | Kevin J. Buehler | Network | E-mail |
| VP Investor Relations and Strategic Corporate Communications | Doug MacHatton | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Alcon News
- Surgical cassette having an aspiration pressure sensor [U.S. Patents] (08 Jul 2008 17:03:00 EDT)
- METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR [PCT Biblio Info] (08 Jul 2008 17:01:00 EDT)
- USE OF SERUM AMYLOID A GENE IN DIAGNOSIS AND TREATMENT OF GLAUCOMA AND IDENTIFICATION OF ANTI-GLAUCOMA AGENTS [PCT Biblio Info] (08 Jul 2008 17:00:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.